Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors. Academic Article uri icon

Overview

abstract

  • The antitumor effector T helper 1 (Th1) and Th17 cells represent two T cell paradigms: short-lived cytolytic Th1 cells and "stem cell-like" memory Th17 cells. We report that Th9 cells represent a third paradigm-they are less-exhausted, fully cytolytic, and hyperproliferative. Only tumor-specific Th9 cells completely eradicated advanced tumors, maintained a mature effector cell signature with cytolytic activity as strong as Th1 cells, and persisted as long as Th17 cells in vivo. Th9 cells displayed a unique Pu.1-Traf6-NF-κB activation-driven hyperproliferative feature, suggesting a persistence mechanism rather than an antiapoptotic strategy. Th9 antitumor efficacy depended on interleukin-9 and upregulated expression of Eomes and Traf6. Thus, tumor-specific Th9 cells are a more effective CD4+ T cell subset for adoptive cancer therapy.

publication date

  • June 11, 2018

Research

keywords

  • CD4-Positive T-Lymphocytes
  • Interleukin-9
  • Melanoma, Experimental
  • T-Lymphocyte Subsets
  • T-Lymphocytes, Helper-Inducer

Identity

PubMed Central ID

  • PMC6072282

Scopus Document Identifier

  • 85047257193

Digital Object Identifier (DOI)

  • 10.1016/j.ccell.2018.05.004

PubMed ID

  • 29894691

Additional Document Info

volume

  • 33

issue

  • 6